SlideShare a Scribd company logo
APPLICATION OF
NEXT GENERATION SEQUENCING (NGS)
IN CANCER TREATMENT
Group 5
Waode Lornawati 0327027
Mush K Zehra 0326829
Dinie Aqilah Ahmad Fariz 0330846
Sivaranjani Thiagarajah 0331182
DNA SEQUENCING
Basic Concept & Principle
What is Next-Generation Sequencing?
● Massively parallel (Corless, 2016).
● Powerful platform that has enabled
the sequencing of thousands to
millions of DNA molecules
simultaneously.
● Revolutionizing fields : by offering a
high throughput option with the
capability to sequence multiple
individuals at the same time
(Bräutigam and Gowik, 2010).
● Perform sequencing of millions of
small fragments of DNA in parallel
(Bräutigam and Gowik, 2010).
● Providing high depth to deliver
accurate data and an insight into
unexpected DNA variation (Gagan
and Van Allen, 2015).
● Combination of template preparation,
sequencing and imaging, and genome
alignment and assembly methods.
● Highly scalable, rapid, affordable, and
accurate genome analysis (Corless,
2016).
Before NGS
● Tumor genotyping was performed only on specific
genomic loci that were known to be frequently mutated in
cancer, “hotspots” .(Gagan and Van Allen, 2015).
● Best suited to recurrent activating mutations in oncogenes
(Gagan and Van Allen, 2015).
● However, these approaches were insufficient to identify
alterations in tumor suppressors.
● in which an alteration anywhere in the gene may impact
its function or the increasingly complex area of “long tail”
hotspot alterations in oncogenes.
● Thus, current assay options involve approaches that may
capture known whole-genome whole-transcriptome
approaches (Bräutigam and Gowik, 2010).
Why NGS is Important in Cancer Treatment?
● Significant impact on the detection, management and treatment of disease.
● Significant improvements in the reliability, sequencing chemistry, pipeline analyses, data
interpretation and costs (Bräutigam and Gowik, 2010).
● Captures a broader spectrum of mutations than Sanger sequencing
● Genomes can be interrogated without bias (Gagan and Van Allen, 2015).
● The increased sensitivity of NGS allows detection of mosaic mutation (Gagan and Van
Allen, 2015).
Sequencing
● Roche/454 FLX
● Illumina/ Solexa
Genome
Analyzer
● Applied
Biosystems (ABI)
SOLiD Analyzer
● Polonator G.007
● Helicos
HeliScope
APPLICATIONS & IMPLICATIONS
Integrated Next Generation Sequencing and Avatar
Mouse Models for Personalized Cancer Treatment
First experiences to apply exome sequencing and
patients derived xenografts, developed in mice
from patient’s tumour tissues so called Avatar
mouse models, to personalizing cancer treatment
in the clinic in a real time.
Method used : Whole exome sequencing analysis
Sample : 25 patients with
advanced solid tumors
Avatar models were used as an in vivo platform to
test proposed treatment strategies.
Whole Exome Sequencing Analysis
● Genomic DNA from tumor and normal samples obtained from blood were
fragmented and used for Illumina TruSeq library construction (Illumina, San
Diego, CA).
● Exonic regions were captured in solution using the Agilent SureSelect 51 Mb
kit (version 4).
● Exome sequencing was performed at depths of 75x to >200x depending on
the tumor purity.
● The tags were aligned to the human genome reference sequence (hg18)
using the Eland algorithm of CASAVA 1.7 software (Illumina, San Diego, CA).
● The chastity filter of the BaseCall software of Illumina was used to select
sequence reads for subsequent analysis.
● The ELAND algorithm of CASAVA 1.7 software (Illumina, San Diego, CA) was
then applied to identify point mutations and small insertions and deletions.
● The resulting alterations are compared among tumor and normal sequence
data as well as to databases of known variants to distinguish common
variants, private (rare) germline changes, and potential somatic alterations.
● Potential somatic mutations were filtered and visually inspected. 3 in silico
methods (Polyphen, SIFT, SNP&GO) used in order to estimate the functional
significance of a given confirmed mutation.
Successful exome sequencing analyses
were obtained for 23 patients (2 patients
with pancreatic cancer progressed
rapidly and the procedures were
aborted).
The number of somatic
mutations and CNVs ranged
from 5 to 952 and from 0 to
965 respectively
The median number of
mutations was 45 and
median CNV was 6
The most relevant
alterations and the clinical
actionable genetic
alterations that could be
targeted with current drug
are extracted .
Results varied significantly
from one patient to another
with patients
Structural models of PI3K. Kinase domain in yellow. Mutated aa in blue.
The model on the right shows the original protein with original aa whereas
the left depicts predictive model of structural changes caused by the
mutation. Severity of the mutation estimated to be high by computational
analysis.
- Example: Patient 3
- Exome sequencing detected the p.F909C mutation in the
catalytic domain of the phosphoinositide 3-kinase protein,
leading to a volume change (from bulky F to a smaller C)
with the introduction of possible S-S bonds
- The severity is high
- Presence of GNG11 amplification suggested activation of
the Ras-Raf-MEK pathway in this tumor with wild type RAS
and RAF genes
Representative tumor growth curve of Avatar PGDX7 treated with the studied agents. PI3i: 20 mg/kg
p.o.; qd, M-F, x28d. MEKi: 4mg/kg p.o.; qd, M-F, x28d. PI3Ki + MEKi: 20 mg/kg p.o + 4 mg/kg p.o.; qd,
M-F, x28d. PI3Ki+Gemcitabine: 20 mg/kg p.o.; qd, M-F, x28d + 100 mg/kg i.p.; twice a week x28d.
Treatment with a PI3K inhibitor alone did not show evidence of
tumor control. The combination of a PI3K and MEK inhibitors is
showed to be a possible effective approach. There’s no access to
such a combination in the clinic to offer the patient. Gemcitabine
was also effective, but the patient had already failed this
treatment previously as he had initially been diagnosed as a
pancreatic adenocarcinoma in another center.
Liquid Biopsy Analyses
● Help early detection of tumour cells during the initial colonising process that
leads to the formation of metastatic tumours
○ Sample: CTC extracted from the plasma including a variety of cancers
○ Screening by: 54-gene-panel/NGS
○ Result: 65% of the different cancer types had detectable ctDNA
aberration and most were theoretically actionable.
● In a study on patients with colorectal cancer:
○ Sample: 68 colorectal cancer-associated genes
○ Screening by: NGS in primary tumour, metastases and CTC (circulating
tumour cells)
○ Result: CTC contained several additional mutations, comparatively (the
origin of tumour metastasis)
● Forshew et al., 2012 developed a tagged-amplicon deep sequencing (TAm-Seq)
method. NGS used to identify mutations and design primers to amplify
approximately 6000 bases that covered the selected regions of cancer-related
genes, including EGFR, TP53, and KRAS.
○ Samples: plasma
○ They showed that the method could identify mutations in TP53 at allelic
frequencies of 2% to 65%, demonstrating that it is feasible to sequence
large regions of circulating DNA by NGS.
The assessment of mutations in EGFR by CTC-NGS analysis can
be used to optimise pharmacologic treatment in patients with
non-small cell lung cancer.
High sensitivity and specificity of NGS was demonstrated in a
screening of plasma samples for lung cancer patients
Through the analysis of ctDNA in plasma samples from ovarian or
breast cancer patients, tumour mutations in TP53 and EGFR
genes were identified.
Cancer Somatic Mutation Analysis
● One of the first reports demonstrating the potential of NGS using the
Illumina Genome Analyser proved that NGS technology was able to
overcome the shortcomings of other technologies which were insensitive,
inaccurate and labour intensive.
● Ley et al., 2008 described the sequencing and analyses of the complete
exonic and regulatory DNA regions in one patient with acute myeloid
leukaemia using both Illumina® and Roche 454® platforms
● Performed a similar analysis on a second acute myeloid leukaemia patient in
2009 comparing the genetic mutations in tumour and matched normal skin
DNA.
○ Four of the 64 mutations identified occurred in at least one additional
patient (out of 188)
○ Somatic mutations were frequently observed in the same specific
genes (like IDH1 gene, which was mutated in more than 8% of the
samples)
○ Prove that NGS is able to identify such alterations.
Roche 454
Illumina genome analyser
Data Analysis &
Computing Infrastructure
● Hundreds of gigabytes of data will
be generated from NGS- difficult to
filter redundant and huge amounts
of data.
● Specialized programs must be used
for most NGS projects.
● Storing, processing, and analyzing
NGS data must be done on a high-
performance computer- impractical
for small diagnostic laboratories and
clinics (costly).
● NGS platforms (Miseq and Ion
torrent) have low throughput which
restricts their applications.
Interpretation of Variation Data
● Interpretation and clinical translation
of data collected on genetic variants
remains a bottleneck for routine
adoption of NGS.
● Difficult to accurately define clinically
significant variants or to effectively
assess disease risk based on current
research (Foretova et al., 2004 and
Maillet et al., 2006).
● For personalized cancer treatment,
filtering out tumor-promoting
mutations from passenger mutations
is also a challenge as the roles of both
may change as the tumor develops
(Ellis et al., 2012).
Ethical Issues
● Legal and ethical concerns for DNA sequencing.
● Disclosure of a patient's genetic testing result may
lead to discrimination based on genetic information
and social disorder, especially in job-hunting and
applications for health insurance.
CHALLENGES
2
3
1
Single Molecule Real-Time (SMRT) Sequencing
by Pacific Biosciences (PacBio)
PacBio data differs from short read sequencing technologies in several aspects:
● Fewer but longer reads.
● Permit sequencing/assembly through repetitive elements, direct variant
phasing, and even direct detection of epigenetic modifications (Flusberg
et al., 2010 and Jain et al, 2016).
● Sequencing only lasts several hours.
● Biases such as GC-skewing are near absent.
● Error types (more indels than mismatches).
● Higher abundance (∼13–15%) though they are spread randomly across the
reads. This randomness enables
● Highly accurate consensuses (>99%) to be build up rapidly by sequencing
multiple times the same molecule (CCS reads) (Eid, 2009) or by
combining different CLRs derived from the same locus
- Eliminates the need for fragmentation, instead sequencing cDNAs from
the 5 end of transcripts to the poly-A tail, termed Iso-Seq.
- Can be used to determine the repeat size and the detection of the
number of interrupting AGG units- unambiguous separation of the two
CGG repeats on the different X chromosomes of females.
- Detection of TKI resistance mutations down to a level of 1%, a
significantly lower detection threshold (compared to the 15–20%
reached by Sanger sequencing.
Figure 1: Overview of SMRT Sequencing Technology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861413/
Bräutigam, A. and Gowik, U. (2010). What can next generation sequencing do for you? Next generation sequencing as a valuable tool in plant research. Plant Biology, [online] 12(6), pp.831-
841. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841808/ [Accessed 18 Oct. 2018].
Corless, C. (2016). Next-Generation Sequencing in Cancer Diagnostics. The Journal of Molecular Diagnostics, 18(6), pp.813-816.
Eid,J., Fehr,A., Gray,J., Luong,K., Lyle,J., Otto,G., Peluso,P., Rank,D., Baybayan,P., Bettman,B. et al. (2009) Real-time DNA sequencing from single polymerase molecules. Science, 323, 133–
138.
Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353–360. [PMC free article] [PubMed]
Flusberg,B.A., Webster,D.R., Lee,J.H., Travers,K.J., Olivares,E.C., Clark,T.A., Korlach,J. and Turner,S.W. (2010) Direct detection of DNA methylation during single-molecule, real-time
sequencing. Nat. Methods, 7, 461–465.
Foretova L, Machackova E, Navratilova M, et al. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Hum Mutat. 2004;23:397–
398.[PubMed]
Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D., Kaper, F., Dawson, S., Piskorz, A., Jimenez-Linan, M., Bentley, D., Hadfield, J., May, A., Caldas, C., Brenton, J. and Rosenfeld, N.
(2012). Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA. Science Translational Medicine, 4(136), pp.136ra68-136ra68.
Gagan, J. and Van Allen, E. (2015). Next-generation sequencing to guide cancer therapy. Genome Medicine, 7(1).
Garralda, E., Paz, K., Lopez-Casas, P., Jones, S., Katz, A., Kann, L., Lopez-Rios, F., Sarno, F., Al-Shahrour, F., Vasquez, D., Bruckheimer, E., Angiuoli, S., Calles, A., Diaz, L., Velculescu, V., Valencia,
A., Sidransky, D. and Hidalgo, M. (2014). Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. Clinical Cancer Research, 20(9), pp.2476-
2484.
Jain,M., Olsen,H.E., Paten,B. and Akeson,M. (2016) The Oxford Nanopore MinION: delivery of nanopore sequencing to the genomics community. Genome Biol., 17, 239.
Ley, T., Mardis, E., Ding, L., Fulton, B., McLellan, M., Chen, K., Dooling, D., Dunford-Shore, B., McGrath, S., Hickenbotham, M., Cook, L., Abbott, R., Larson, D., Koboldt, D., Pohl, C., Smith, S.,
Hawkins, A., Abbott, S., Locke, D., Hillier, L., Miner, T., Fulton, L., Magrini, V., Wylie, T., Glasscock, J., Conyers, J., Sander, N., Shi, X., Osborne, J., Minx, P., Gordon, D., Chinwalla, A., Zhao, Y.,
Ries, R., Payton, J., Westervelt, P., Tomasson, M., Watson, M., Baty, J., Ivanovich, J., Heath, S., Shannon, W., Nagarajan, R., Walter, M., Link, D., Graubert, T., DiPersio, J. and Wilson, R.
(2008). DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 456(7218), pp.66-72.
Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med. 2010;362:1181–
91.
REFERENCES

More Related Content

What's hot

Microarray CGH
Microarray CGHMicroarray CGH
Microarray CGH
Pinal Chaudhari
 
Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...
Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...
Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...
QIAGEN
 
Next_generation_sequencing_AKT_Nov14
Next_generation_sequencing_AKT_Nov14Next_generation_sequencing_AKT_Nov14
Next_generation_sequencing_AKT_Nov14
Office of Health Economics
 
Precision Medicine in Oncology
Precision Medicine in OncologyPrecision Medicine in Oncology
Precision Medicine in Oncology
Canadian Cancer Survivor Network
 
CTCs - Circulating Tumor Cells
CTCs - Circulating Tumor CellsCTCs - Circulating Tumor Cells
CTCs - Circulating Tumor Cells
Sreepadmanabh M
 
Integration of NGS in Current & FutureTreatment Algorithm of Colorectal Cancer
Integration of NGS in Current & FutureTreatment Algorithm of Colorectal CancerIntegration of NGS in Current & FutureTreatment Algorithm of Colorectal Cancer
Integration of NGS in Current & FutureTreatment Algorithm of Colorectal Cancer
Mohamed Abdulla
 
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
QIAGEN
 
Chapter 2.1 mi rna
Chapter 2.1 mi rnaChapter 2.1 mi rna
Chapter 2.1 mi rna
Nilesh Kucha
 
Liquid Biopsy in Oncology: Non-Invasive Diagnosis for Cancer Patients
Liquid Biopsy in Oncology�: Non-Invasive Diagnosis for Cancer PatientsLiquid Biopsy in Oncology�: Non-Invasive Diagnosis for Cancer Patients
Liquid Biopsy in Oncology: Non-Invasive Diagnosis for Cancer Patients
Kumaraguru Veerasamy
 
Salisha ppt (1) (1)
Salisha ppt (1) (1)Salisha ppt (1) (1)
Salisha ppt (1) (1)
Santhi Dasari
 
Liquid biopsy
Liquid biopsyLiquid biopsy
Liquid biopsy
Dr kusuma
 
The Cancer Genome Atlas Update
The Cancer Genome Atlas UpdateThe Cancer Genome Atlas Update
The Cancer Genome Atlas Update
Melanoma Research Foundation
 
Ca ncer proteomics
Ca ncer proteomicsCa ncer proteomics
Ca ncer proteomics
SuganyaPaulraj
 
CCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careCCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careAdonis Guancia
 
Aviad Zick. Role of BRCA status in treatment planning
Aviad Zick. Role of BRCA status in treatment planningAviad Zick. Role of BRCA status in treatment planning
Aviad Zick. Role of BRCA status in treatment planningbreastcancerupdatecongress
 
Hr+ her2 neu mbc
Hr+ her2 neu   mbcHr+ her2 neu   mbc
Hr+ her2 neu mbc
madurai
 
Breast Cancer: A focus on BRCA Mutations.
Breast Cancer: A focus on BRCA Mutations.Breast Cancer: A focus on BRCA Mutations.
Breast Cancer: A focus on BRCA Mutations.
Mohamed Abdulla
 
Understanding BRCA1/2 Cancer Risk
Understanding BRCA1/2 Cancer RiskUnderstanding BRCA1/2 Cancer Risk
Understanding BRCA1/2 Cancer Risk
Dana-Farber Cancer Institute
 

What's hot (20)

Microarray CGH
Microarray CGHMicroarray CGH
Microarray CGH
 
Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...
Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...
Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...
 
Next_generation_sequencing_AKT_Nov14
Next_generation_sequencing_AKT_Nov14Next_generation_sequencing_AKT_Nov14
Next_generation_sequencing_AKT_Nov14
 
Precision Medicine in Oncology
Precision Medicine in OncologyPrecision Medicine in Oncology
Precision Medicine in Oncology
 
CTCs - Circulating Tumor Cells
CTCs - Circulating Tumor CellsCTCs - Circulating Tumor Cells
CTCs - Circulating Tumor Cells
 
Integration of NGS in Current & FutureTreatment Algorithm of Colorectal Cancer
Integration of NGS in Current & FutureTreatment Algorithm of Colorectal CancerIntegration of NGS in Current & FutureTreatment Algorithm of Colorectal Cancer
Integration of NGS in Current & FutureTreatment Algorithm of Colorectal Cancer
 
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
 
Chapter 2.1 mi rna
Chapter 2.1 mi rnaChapter 2.1 mi rna
Chapter 2.1 mi rna
 
Liquid Biopsy in Oncology: Non-Invasive Diagnosis for Cancer Patients
Liquid Biopsy in Oncology�: Non-Invasive Diagnosis for Cancer PatientsLiquid Biopsy in Oncology�: Non-Invasive Diagnosis for Cancer Patients
Liquid Biopsy in Oncology: Non-Invasive Diagnosis for Cancer Patients
 
Salisha ppt (1) (1)
Salisha ppt (1) (1)Salisha ppt (1) (1)
Salisha ppt (1) (1)
 
Liquid biopsy
Liquid biopsyLiquid biopsy
Liquid biopsy
 
The Cancer Genome Atlas Update
The Cancer Genome Atlas UpdateThe Cancer Genome Atlas Update
The Cancer Genome Atlas Update
 
Ca ncer proteomics
Ca ncer proteomicsCa ncer proteomics
Ca ncer proteomics
 
Translating next generation sequencing to practice
Translating next generation sequencing to practiceTranslating next generation sequencing to practice
Translating next generation sequencing to practice
 
Targeted cancer therapies
Targeted cancer therapiesTargeted cancer therapies
Targeted cancer therapies
 
CCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careCCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_care
 
Aviad Zick. Role of BRCA status in treatment planning
Aviad Zick. Role of BRCA status in treatment planningAviad Zick. Role of BRCA status in treatment planning
Aviad Zick. Role of BRCA status in treatment planning
 
Hr+ her2 neu mbc
Hr+ her2 neu   mbcHr+ her2 neu   mbc
Hr+ her2 neu mbc
 
Breast Cancer: A focus on BRCA Mutations.
Breast Cancer: A focus on BRCA Mutations.Breast Cancer: A focus on BRCA Mutations.
Breast Cancer: A focus on BRCA Mutations.
 
Understanding BRCA1/2 Cancer Risk
Understanding BRCA1/2 Cancer RiskUnderstanding BRCA1/2 Cancer Risk
Understanding BRCA1/2 Cancer Risk
 

Similar to APPLICATION OF NEXT GENERATION SEQUENCING (NGS) IN CANCER TREATMENT

Next Generation Sequencing
Next Generation SequencingNext Generation Sequencing
Next Generation Sequencing
Shelomi Karoon
 
Role of biotechnology in cancer control
Role of biotechnology in cancer controlRole of biotechnology in cancer control
Role of biotechnology in cancer control
Janani Gopalarethinam
 
Next generation sequencing in cancer treatment
Next generation sequencing in cancer treatment  Next generation sequencing in cancer treatment
Next generation sequencing in cancer treatment
MarliaGan
 
GTC group 8 - Next Generation Sequencing
GTC group 8 - Next Generation SequencingGTC group 8 - Next Generation Sequencing
GTC group 8 - Next Generation Sequencing
Yanqi Chan
 
Biomed central
Biomed centralBiomed central
Developing a framework for for detection of low frequency somatic genetic alt...
Developing a framework for for detection of low frequency somatic genetic alt...Developing a framework for for detection of low frequency somatic genetic alt...
Developing a framework for for detection of low frequency somatic genetic alt...
Ronak Shah
 
Ong et al._Translational utility of next-generation sequencing_2013_Genomics
Ong et al._Translational utility of next-generation sequencing_2013_GenomicsOng et al._Translational utility of next-generation sequencing_2013_Genomics
Ong et al._Translational utility of next-generation sequencing_2013_GenomicsFrank Ong, MD, CPI
 
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...European School of Oncology
 
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...European School of Oncology
 
Introduction to cancer bioinformatics
Introduction to cancer bioinformaticsIntroduction to cancer bioinformatics
Introduction to cancer bioinformatics
creativebiolabs11
 
S13148 019-0757-3
S13148 019-0757-3S13148 019-0757-3
S13148 019-0757-3
ssuserb39d8a
 
Geveart Lab SIMR Paper
Geveart Lab SIMR PaperGeveart Lab SIMR Paper
Geveart Lab SIMR PaperNathan Dalal
 
Translating Genomes | Personalizing Medicine
Translating Genomes | Personalizing MedicineTranslating Genomes | Personalizing Medicine
Translating Genomes | Personalizing Medicine
Candy Smellie
 
High Sensitivity Detection of Tumor Gene Mutations-v3
High Sensitivity Detection of Tumor Gene Mutations-v3High Sensitivity Detection of Tumor Gene Mutations-v3
High Sensitivity Detection of Tumor Gene Mutations-v3Michael Powell
 
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
Tobias Meißner
 
Genome wide study
Genome wide studyGenome wide study
Genome wide study
Government Medical College
 
Methods, Challenges and Future Directions of Radiogenomics-Crimson Publishers
Methods, Challenges and Future Directions of Radiogenomics-Crimson PublishersMethods, Challenges and Future Directions of Radiogenomics-Crimson Publishers
Methods, Challenges and Future Directions of Radiogenomics-Crimson Publishers
CrimsonpublishersCancer
 
Mining Gene Expression Data Focusing Cancer Therapeutics: A Digest
Mining Gene Expression Data Focusing Cancer Therapeutics: A DigestMining Gene Expression Data Focusing Cancer Therapeutics: A Digest
Mining Gene Expression Data Focusing Cancer Therapeutics: A Digest
KaashivInfoTech Company
 

Similar to APPLICATION OF NEXT GENERATION SEQUENCING (NGS) IN CANCER TREATMENT (20)

Next Generation Sequencing
Next Generation SequencingNext Generation Sequencing
Next Generation Sequencing
 
Role of biotechnology in cancer control
Role of biotechnology in cancer controlRole of biotechnology in cancer control
Role of biotechnology in cancer control
 
s12935-014-0115-7
s12935-014-0115-7s12935-014-0115-7
s12935-014-0115-7
 
Next generation sequencing in cancer treatment
Next generation sequencing in cancer treatment  Next generation sequencing in cancer treatment
Next generation sequencing in cancer treatment
 
GTC group 8 - Next Generation Sequencing
GTC group 8 - Next Generation SequencingGTC group 8 - Next Generation Sequencing
GTC group 8 - Next Generation Sequencing
 
Biomed central
Biomed centralBiomed central
Biomed central
 
Developing a framework for for detection of low frequency somatic genetic alt...
Developing a framework for for detection of low frequency somatic genetic alt...Developing a framework for for detection of low frequency somatic genetic alt...
Developing a framework for for detection of low frequency somatic genetic alt...
 
Perosnalized
PerosnalizedPerosnalized
Perosnalized
 
Ong et al._Translational utility of next-generation sequencing_2013_Genomics
Ong et al._Translational utility of next-generation sequencing_2013_GenomicsOng et al._Translational utility of next-generation sequencing_2013_Genomics
Ong et al._Translational utility of next-generation sequencing_2013_Genomics
 
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...
 
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
 
Introduction to cancer bioinformatics
Introduction to cancer bioinformaticsIntroduction to cancer bioinformatics
Introduction to cancer bioinformatics
 
S13148 019-0757-3
S13148 019-0757-3S13148 019-0757-3
S13148 019-0757-3
 
Geveart Lab SIMR Paper
Geveart Lab SIMR PaperGeveart Lab SIMR Paper
Geveart Lab SIMR Paper
 
Translating Genomes | Personalizing Medicine
Translating Genomes | Personalizing MedicineTranslating Genomes | Personalizing Medicine
Translating Genomes | Personalizing Medicine
 
High Sensitivity Detection of Tumor Gene Mutations-v3
High Sensitivity Detection of Tumor Gene Mutations-v3High Sensitivity Detection of Tumor Gene Mutations-v3
High Sensitivity Detection of Tumor Gene Mutations-v3
 
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
 
Genome wide study
Genome wide studyGenome wide study
Genome wide study
 
Methods, Challenges and Future Directions of Radiogenomics-Crimson Publishers
Methods, Challenges and Future Directions of Radiogenomics-Crimson PublishersMethods, Challenges and Future Directions of Radiogenomics-Crimson Publishers
Methods, Challenges and Future Directions of Radiogenomics-Crimson Publishers
 
Mining Gene Expression Data Focusing Cancer Therapeutics: A Digest
Mining Gene Expression Data Focusing Cancer Therapeutics: A DigestMining Gene Expression Data Focusing Cancer Therapeutics: A Digest
Mining Gene Expression Data Focusing Cancer Therapeutics: A Digest
 

Recently uploaded

general properties of oerganologametal.ppt
general properties of oerganologametal.pptgeneral properties of oerganologametal.ppt
general properties of oerganologametal.ppt
IqrimaNabilatulhusni
 
Structural Classification Of Protein (SCOP)
Structural Classification Of Protein  (SCOP)Structural Classification Of Protein  (SCOP)
Structural Classification Of Protein (SCOP)
aishnasrivastava
 
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of LipidsGBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
Areesha Ahmad
 
Lab report on liquid viscosity of glycerin
Lab report on liquid viscosity of glycerinLab report on liquid viscosity of glycerin
Lab report on liquid viscosity of glycerin
ossaicprecious19
 
Cancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate PathwayCancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate Pathway
AADYARAJPANDEY1
 
Predicting property prices with machine learning algorithms.pdf
Predicting property prices with machine learning algorithms.pdfPredicting property prices with machine learning algorithms.pdf
Predicting property prices with machine learning algorithms.pdf
binhminhvu04
 
Penicillin...........................pptx
Penicillin...........................pptxPenicillin...........................pptx
Penicillin...........................pptx
Cherry
 
Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...
Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...
Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...
NathanBaughman3
 
platelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptxplatelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptx
muralinath2
 
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
Sérgio Sacani
 
NuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final versionNuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final version
pablovgd
 
FAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable PredictionsFAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable Predictions
Michel Dumontier
 
Hemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptxHemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptx
muralinath2
 
Nutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technologyNutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technology
Lokesh Patil
 
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdfSCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SELF-EXPLANATORY
 
Mammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also FunctionsMammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also Functions
YOGESH DOGRA
 
Viksit bharat till 2047 India@2047.pptx
Viksit bharat till 2047  India@2047.pptxViksit bharat till 2047  India@2047.pptx
Viksit bharat till 2047 India@2047.pptx
rakeshsharma20142015
 
Citrus Greening Disease and its Management
Citrus Greening Disease and its ManagementCitrus Greening Disease and its Management
Citrus Greening Disease and its Management
subedisuryaofficial
 
Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...
Sérgio Sacani
 
justice-and-fairness-ethics with example
justice-and-fairness-ethics with examplejustice-and-fairness-ethics with example
justice-and-fairness-ethics with example
azzyixes
 

Recently uploaded (20)

general properties of oerganologametal.ppt
general properties of oerganologametal.pptgeneral properties of oerganologametal.ppt
general properties of oerganologametal.ppt
 
Structural Classification Of Protein (SCOP)
Structural Classification Of Protein  (SCOP)Structural Classification Of Protein  (SCOP)
Structural Classification Of Protein (SCOP)
 
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of LipidsGBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
 
Lab report on liquid viscosity of glycerin
Lab report on liquid viscosity of glycerinLab report on liquid viscosity of glycerin
Lab report on liquid viscosity of glycerin
 
Cancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate PathwayCancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate Pathway
 
Predicting property prices with machine learning algorithms.pdf
Predicting property prices with machine learning algorithms.pdfPredicting property prices with machine learning algorithms.pdf
Predicting property prices with machine learning algorithms.pdf
 
Penicillin...........................pptx
Penicillin...........................pptxPenicillin...........................pptx
Penicillin...........................pptx
 
Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...
Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...
Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...
 
platelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptxplatelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptx
 
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
 
NuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final versionNuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final version
 
FAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable PredictionsFAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable Predictions
 
Hemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptxHemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptx
 
Nutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technologyNutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technology
 
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdfSCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
 
Mammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also FunctionsMammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also Functions
 
Viksit bharat till 2047 India@2047.pptx
Viksit bharat till 2047  India@2047.pptxViksit bharat till 2047  India@2047.pptx
Viksit bharat till 2047 India@2047.pptx
 
Citrus Greening Disease and its Management
Citrus Greening Disease and its ManagementCitrus Greening Disease and its Management
Citrus Greening Disease and its Management
 
Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...
 
justice-and-fairness-ethics with example
justice-and-fairness-ethics with examplejustice-and-fairness-ethics with example
justice-and-fairness-ethics with example
 

APPLICATION OF NEXT GENERATION SEQUENCING (NGS) IN CANCER TREATMENT

  • 1. APPLICATION OF NEXT GENERATION SEQUENCING (NGS) IN CANCER TREATMENT Group 5 Waode Lornawati 0327027 Mush K Zehra 0326829 Dinie Aqilah Ahmad Fariz 0330846 Sivaranjani Thiagarajah 0331182
  • 2. DNA SEQUENCING Basic Concept & Principle What is Next-Generation Sequencing? ● Massively parallel (Corless, 2016). ● Powerful platform that has enabled the sequencing of thousands to millions of DNA molecules simultaneously. ● Revolutionizing fields : by offering a high throughput option with the capability to sequence multiple individuals at the same time (Bräutigam and Gowik, 2010). ● Perform sequencing of millions of small fragments of DNA in parallel (Bräutigam and Gowik, 2010). ● Providing high depth to deliver accurate data and an insight into unexpected DNA variation (Gagan and Van Allen, 2015). ● Combination of template preparation, sequencing and imaging, and genome alignment and assembly methods. ● Highly scalable, rapid, affordable, and accurate genome analysis (Corless, 2016). Before NGS ● Tumor genotyping was performed only on specific genomic loci that were known to be frequently mutated in cancer, “hotspots” .(Gagan and Van Allen, 2015). ● Best suited to recurrent activating mutations in oncogenes (Gagan and Van Allen, 2015). ● However, these approaches were insufficient to identify alterations in tumor suppressors. ● in which an alteration anywhere in the gene may impact its function or the increasingly complex area of “long tail” hotspot alterations in oncogenes. ● Thus, current assay options involve approaches that may capture known whole-genome whole-transcriptome approaches (Bräutigam and Gowik, 2010). Why NGS is Important in Cancer Treatment? ● Significant impact on the detection, management and treatment of disease. ● Significant improvements in the reliability, sequencing chemistry, pipeline analyses, data interpretation and costs (Bräutigam and Gowik, 2010). ● Captures a broader spectrum of mutations than Sanger sequencing ● Genomes can be interrogated without bias (Gagan and Van Allen, 2015). ● The increased sensitivity of NGS allows detection of mosaic mutation (Gagan and Van Allen, 2015). Sequencing ● Roche/454 FLX ● Illumina/ Solexa Genome Analyzer ● Applied Biosystems (ABI) SOLiD Analyzer ● Polonator G.007 ● Helicos HeliScope
  • 3. APPLICATIONS & IMPLICATIONS Integrated Next Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment First experiences to apply exome sequencing and patients derived xenografts, developed in mice from patient’s tumour tissues so called Avatar mouse models, to personalizing cancer treatment in the clinic in a real time. Method used : Whole exome sequencing analysis Sample : 25 patients with advanced solid tumors Avatar models were used as an in vivo platform to test proposed treatment strategies. Whole Exome Sequencing Analysis ● Genomic DNA from tumor and normal samples obtained from blood were fragmented and used for Illumina TruSeq library construction (Illumina, San Diego, CA). ● Exonic regions were captured in solution using the Agilent SureSelect 51 Mb kit (version 4). ● Exome sequencing was performed at depths of 75x to >200x depending on the tumor purity. ● The tags were aligned to the human genome reference sequence (hg18) using the Eland algorithm of CASAVA 1.7 software (Illumina, San Diego, CA). ● The chastity filter of the BaseCall software of Illumina was used to select sequence reads for subsequent analysis. ● The ELAND algorithm of CASAVA 1.7 software (Illumina, San Diego, CA) was then applied to identify point mutations and small insertions and deletions. ● The resulting alterations are compared among tumor and normal sequence data as well as to databases of known variants to distinguish common variants, private (rare) germline changes, and potential somatic alterations. ● Potential somatic mutations were filtered and visually inspected. 3 in silico methods (Polyphen, SIFT, SNP&GO) used in order to estimate the functional significance of a given confirmed mutation.
  • 4. Successful exome sequencing analyses were obtained for 23 patients (2 patients with pancreatic cancer progressed rapidly and the procedures were aborted).
  • 5. The number of somatic mutations and CNVs ranged from 5 to 952 and from 0 to 965 respectively The median number of mutations was 45 and median CNV was 6 The most relevant alterations and the clinical actionable genetic alterations that could be targeted with current drug are extracted . Results varied significantly from one patient to another with patients
  • 6. Structural models of PI3K. Kinase domain in yellow. Mutated aa in blue. The model on the right shows the original protein with original aa whereas the left depicts predictive model of structural changes caused by the mutation. Severity of the mutation estimated to be high by computational analysis. - Example: Patient 3 - Exome sequencing detected the p.F909C mutation in the catalytic domain of the phosphoinositide 3-kinase protein, leading to a volume change (from bulky F to a smaller C) with the introduction of possible S-S bonds - The severity is high - Presence of GNG11 amplification suggested activation of the Ras-Raf-MEK pathway in this tumor with wild type RAS and RAF genes Representative tumor growth curve of Avatar PGDX7 treated with the studied agents. PI3i: 20 mg/kg p.o.; qd, M-F, x28d. MEKi: 4mg/kg p.o.; qd, M-F, x28d. PI3Ki + MEKi: 20 mg/kg p.o + 4 mg/kg p.o.; qd, M-F, x28d. PI3Ki+Gemcitabine: 20 mg/kg p.o.; qd, M-F, x28d + 100 mg/kg i.p.; twice a week x28d. Treatment with a PI3K inhibitor alone did not show evidence of tumor control. The combination of a PI3K and MEK inhibitors is showed to be a possible effective approach. There’s no access to such a combination in the clinic to offer the patient. Gemcitabine was also effective, but the patient had already failed this treatment previously as he had initially been diagnosed as a pancreatic adenocarcinoma in another center.
  • 7.
  • 8. Liquid Biopsy Analyses ● Help early detection of tumour cells during the initial colonising process that leads to the formation of metastatic tumours ○ Sample: CTC extracted from the plasma including a variety of cancers ○ Screening by: 54-gene-panel/NGS ○ Result: 65% of the different cancer types had detectable ctDNA aberration and most were theoretically actionable. ● In a study on patients with colorectal cancer: ○ Sample: 68 colorectal cancer-associated genes ○ Screening by: NGS in primary tumour, metastases and CTC (circulating tumour cells) ○ Result: CTC contained several additional mutations, comparatively (the origin of tumour metastasis) ● Forshew et al., 2012 developed a tagged-amplicon deep sequencing (TAm-Seq) method. NGS used to identify mutations and design primers to amplify approximately 6000 bases that covered the selected regions of cancer-related genes, including EGFR, TP53, and KRAS. ○ Samples: plasma ○ They showed that the method could identify mutations in TP53 at allelic frequencies of 2% to 65%, demonstrating that it is feasible to sequence large regions of circulating DNA by NGS. The assessment of mutations in EGFR by CTC-NGS analysis can be used to optimise pharmacologic treatment in patients with non-small cell lung cancer. High sensitivity and specificity of NGS was demonstrated in a screening of plasma samples for lung cancer patients Through the analysis of ctDNA in plasma samples from ovarian or breast cancer patients, tumour mutations in TP53 and EGFR genes were identified.
  • 9. Cancer Somatic Mutation Analysis ● One of the first reports demonstrating the potential of NGS using the Illumina Genome Analyser proved that NGS technology was able to overcome the shortcomings of other technologies which were insensitive, inaccurate and labour intensive. ● Ley et al., 2008 described the sequencing and analyses of the complete exonic and regulatory DNA regions in one patient with acute myeloid leukaemia using both Illumina® and Roche 454® platforms ● Performed a similar analysis on a second acute myeloid leukaemia patient in 2009 comparing the genetic mutations in tumour and matched normal skin DNA. ○ Four of the 64 mutations identified occurred in at least one additional patient (out of 188) ○ Somatic mutations were frequently observed in the same specific genes (like IDH1 gene, which was mutated in more than 8% of the samples) ○ Prove that NGS is able to identify such alterations. Roche 454 Illumina genome analyser
  • 10. Data Analysis & Computing Infrastructure ● Hundreds of gigabytes of data will be generated from NGS- difficult to filter redundant and huge amounts of data. ● Specialized programs must be used for most NGS projects. ● Storing, processing, and analyzing NGS data must be done on a high- performance computer- impractical for small diagnostic laboratories and clinics (costly). ● NGS platforms (Miseq and Ion torrent) have low throughput which restricts their applications. Interpretation of Variation Data ● Interpretation and clinical translation of data collected on genetic variants remains a bottleneck for routine adoption of NGS. ● Difficult to accurately define clinically significant variants or to effectively assess disease risk based on current research (Foretova et al., 2004 and Maillet et al., 2006). ● For personalized cancer treatment, filtering out tumor-promoting mutations from passenger mutations is also a challenge as the roles of both may change as the tumor develops (Ellis et al., 2012). Ethical Issues ● Legal and ethical concerns for DNA sequencing. ● Disclosure of a patient's genetic testing result may lead to discrimination based on genetic information and social disorder, especially in job-hunting and applications for health insurance. CHALLENGES 2 3 1
  • 11. Single Molecule Real-Time (SMRT) Sequencing by Pacific Biosciences (PacBio) PacBio data differs from short read sequencing technologies in several aspects: ● Fewer but longer reads. ● Permit sequencing/assembly through repetitive elements, direct variant phasing, and even direct detection of epigenetic modifications (Flusberg et al., 2010 and Jain et al, 2016). ● Sequencing only lasts several hours. ● Biases such as GC-skewing are near absent. ● Error types (more indels than mismatches). ● Higher abundance (∼13–15%) though they are spread randomly across the reads. This randomness enables ● Highly accurate consensuses (>99%) to be build up rapidly by sequencing multiple times the same molecule (CCS reads) (Eid, 2009) or by combining different CLRs derived from the same locus - Eliminates the need for fragmentation, instead sequencing cDNAs from the 5 end of transcripts to the poly-A tail, termed Iso-Seq. - Can be used to determine the repeat size and the detection of the number of interrupting AGG units- unambiguous separation of the two CGG repeats on the different X chromosomes of females. - Detection of TKI resistance mutations down to a level of 1%, a significantly lower detection threshold (compared to the 15–20% reached by Sanger sequencing. Figure 1: Overview of SMRT Sequencing Technology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861413/
  • 12. Bräutigam, A. and Gowik, U. (2010). What can next generation sequencing do for you? Next generation sequencing as a valuable tool in plant research. Plant Biology, [online] 12(6), pp.831- 841. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841808/ [Accessed 18 Oct. 2018]. Corless, C. (2016). Next-Generation Sequencing in Cancer Diagnostics. The Journal of Molecular Diagnostics, 18(6), pp.813-816. Eid,J., Fehr,A., Gray,J., Luong,K., Lyle,J., Otto,G., Peluso,P., Rank,D., Baybayan,P., Bettman,B. et al. (2009) Real-time DNA sequencing from single polymerase molecules. Science, 323, 133– 138. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353–360. [PMC free article] [PubMed] Flusberg,B.A., Webster,D.R., Lee,J.H., Travers,K.J., Olivares,E.C., Clark,T.A., Korlach,J. and Turner,S.W. (2010) Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat. Methods, 7, 461–465. Foretova L, Machackova E, Navratilova M, et al. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Hum Mutat. 2004;23:397– 398.[PubMed] Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D., Kaper, F., Dawson, S., Piskorz, A., Jimenez-Linan, M., Bentley, D., Hadfield, J., May, A., Caldas, C., Brenton, J. and Rosenfeld, N. (2012). Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA. Science Translational Medicine, 4(136), pp.136ra68-136ra68. Gagan, J. and Van Allen, E. (2015). Next-generation sequencing to guide cancer therapy. Genome Medicine, 7(1). Garralda, E., Paz, K., Lopez-Casas, P., Jones, S., Katz, A., Kann, L., Lopez-Rios, F., Sarno, F., Al-Shahrour, F., Vasquez, D., Bruckheimer, E., Angiuoli, S., Calles, A., Diaz, L., Velculescu, V., Valencia, A., Sidransky, D. and Hidalgo, M. (2014). Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. Clinical Cancer Research, 20(9), pp.2476- 2484. Jain,M., Olsen,H.E., Paten,B. and Akeson,M. (2016) The Oxford Nanopore MinION: delivery of nanopore sequencing to the genomics community. Genome Biol., 17, 239. Ley, T., Mardis, E., Ding, L., Fulton, B., McLellan, M., Chen, K., Dooling, D., Dunford-Shore, B., McGrath, S., Hickenbotham, M., Cook, L., Abbott, R., Larson, D., Koboldt, D., Pohl, C., Smith, S., Hawkins, A., Abbott, S., Locke, D., Hillier, L., Miner, T., Fulton, L., Magrini, V., Wylie, T., Glasscock, J., Conyers, J., Sander, N., Shi, X., Osborne, J., Minx, P., Gordon, D., Chinwalla, A., Zhao, Y., Ries, R., Payton, J., Westervelt, P., Tomasson, M., Watson, M., Baty, J., Ivanovich, J., Heath, S., Shannon, W., Nagarajan, R., Walter, M., Link, D., Graubert, T., DiPersio, J. and Wilson, R. (2008). DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 456(7218), pp.66-72. Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med. 2010;362:1181– 91. REFERENCES

Editor's Notes

  1. to determine the most biologically relevant somatic mutations. non curable advanced cancer with adequate bone marrow, liver and renal function to receive chemotherapy. Generation of Avatar Mouse Models Obtained by a tumor biopsy, transplanted and propagated in nude mice. generated by specimens obtained from fresh biopsies of metastasis Once the tumor specimen was in an exponential growth phase, cohorts of mice with tumor sizes of 0.15 to 0.3 mL were randomized to several treatment groups.
  2. As shown in Table 2, these results varied significantly from one patient to another with patients such as patient #1 with a low grade intestinal neuroendocrine tumor having only one targetable mutation in CREB3L3 and patient # 7 with malignant melanoma with mutations in more than 10 well accepted drug targets such as IGF1R, MET, PI3K and FGFR.
  3. In conclusion, liquid biopsy analyses by NGS and through WES/WGS analyses have been applied to several cancer types. This technique, without the need of an invasive biopsy from the diseased tissue, can help in early detection, monitoring for response to therapy, potential resistance to therapy, influencing the choice for (alternative) therapy.
  4. Overall, these initial studies demonstrated that NGS can identify the full range of somatic alteration in cancer. After 2010, there has been an exponential increase in the use of NGS in cancer somatic mutation detection.